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Background: Zellweger spectrum disorders (ZSDs) are multisystem genetic disorders caused by a lack of functional
peroxisomes, due to mutations in one of the PEX genes, encoding proteins involved in peroxisome biogenesis. The
phenotypic spectrum of ZSDs ranges from an early lethal form to much milder presentations. In cultured skin
fibroblasts from mildly affected patients, peroxisome biogenesis can be partially impaired which results in a mosaic
catalase immunofluorescence pattern. This peroxisomal mosaicism has been described for specific missense
mutations in various PEX genes. In cell lines displaying peroxisomal mosaicism, peroxisome biogenesis can be
improved when these are cultured at 30°C. This suggests that these missense mutations affect the folding and/or
stability of the encoded protein. We have studied if the function of mutant PEX1, PEX6 and PEX12 can be improved
by promoting protein folding using the chemical chaperone arginine.
Methods: Fibroblasts from three PEX1 patients, one PEX6 and one PEX12 patient were cultured in the presence of
different concentrations of arginine. To determine the effect on peroxisome biogenesis we studied the following
parameters: number of peroxisome-positive cells, levels of PEX1 protein and processed thiolase, and the capacity to
β-oxidize very long chain fatty acids and pristanic acid.
Results: Peroxisome biogenesis and function in fibroblasts with mild missense mutations in PEX1, 6 and 12 can be
improved by arginine.
Conclusion: Arginine may be an interesting compound to promote peroxisome function in patients with a mild
peroxisome biogenesis disorder.
Keywords: Peroxisome biogenesis disorder, Zellweger spectrum disorder, Misfolded protein, Peroxisomal mosaicism,
Arginine, TherapyBackground
Peroxisomes are ubiquitous organelles bound by a single
membrane and present in nearly all eukaryotic cells. There
are approximately 50 different peroxisomal enzyme pro-
teins, which are involved in various biochemical path-
ways and can be present in different types of cells. Among
others, peroxisomes are involved in the degradation of Very
Long Chain Fatty Acids (VLCFA; ≥C22:0), the formation* Correspondence: h.r.waterham@amc.uva.nl
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reproduction in any medium, provided the orof bile acids, the synthesis of plasmalogens and the oxi-
dation of phytanic acid [1]. Peroxisome biogenesis disor-
ders (PBDs) are autosomal recessive disorders characterized
by an impairment in one or more peroxisomal functions.
The PBDs can be divided into two subtypes; the Zellweger
Spectrum Disorders (ZSD, OMIM #601539) and rhizomelic
chondrodysplasia punctata type I (RCDP, OMIM #215100).
Clinically and biochemically, the ZSD represent a con-
tinuum of at least three phenotypes, including Zellweger
syndrome (ZS, OMIM #214100) as the most severe, neo-
natal adrenoleukodystrophy (NALD, OMIM #202370), and
infantile Refsum disease (IRD, OMIM # 266510) [2-4] as
the least severe phenotype.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In contrast, cells from NALD and IRD patients still con-
tain functional peroxisomes albeit reduced in number.
When skin fibroblasts from milder patients are cultured
at 37°C and then examined for the localization of the
peroxisomal matrix protein catalase, a mixed population
of cells with either catalase-containing or catalase-lacking
peroxisomes can be seen [5-7]. This phenomenon is
called peroxisomal mosaicism and has been described
for mutations in various PEX genes (e.g. PEX1, PEX2,
PEX6, PEX10 and PEX12), which are associated with a
relatively mild phenotype [5,6,8,9].
Proteins encoded by PEX genes are called peroxins and
play a role in normal peroxisome assembly. Currently 14
peroxins are known to be involved in this process and mu-
tations in 13 of the PEX genes have been associated with
ZSDs [9,10]. When skin fibroblasts, displaying peroxi-
somal mosaicism, are cultured at 30°C, all cells regain
catalase-containing peroxisomes. In contrast, when the
fibroblasts are cultured at 40°C, all cells lose catalase-
containing peroxisomes [5] which resembles the peroxi-
somal phenotype in fibroblasts from classical Zellweger
patients. This suggests that the mutations associated
with peroxisomal mosaicism cause an unstable and/or
incorrectly folded PEX protein. Moreover, these obser-
vations also suggest that improving the folding of the
mutated protein, e.g. by lowering the temperature, can
result in the restoration of peroxisome biogenesis. Here,
we have studied whether the chemical chaperone argin-
ine is also capable of improving peroxisome biogenesis
in fibroblasts displaying peroxisomal mosaicism.
Chemical chaperones are small-molecule osmolytes,
which have the capacity to improve protein folding. Pre-
vious studies have shown that several compounds are
capable of improving peroxisomal function [11]. Arginine
has been described to correct protein folding and suppress
protein aggregation in vitro [12]. Furthermore, it has
been shown that arginine supplementation restored PDHc
function in a patient with pyruvate dehydrogenase
deficiency [13]. The mechanism which underlies its
chaperone function is unknown, but might involve
conformational correction and prevention of nonpro-
ductive protein interactions [14].
In this study, we show that arginine is able to improve
peroxisome biogenesis and functioning in cells from
patients with a mild ZSD, that display peroxisomal mo-




For this study we used primary skin fibroblasts from
different patients with a mild peroxisomal disease. Three
cell lines were homozygous for the c.2528G>A (p.G843D)mutation in the PEX1 gene (PEX1-G843D); one cell line
was compound heterozygous for the c.821C>T (p.P274L)
and c.1314_1321delGGAGGCCT (p.E439fsX3) mutation
in PEX6 and one cell line was homozygous for the
c.959C>T (p.S320F) mutation in the PEX12 gene. As
negative control we used a cell line homozygous for
the c.2097insT (p.I700fsX41) mutation in PEX1 (PEX1-
I700fsX41), which has no functional peroxisomes (Zellweger
syndrome). In accordance with the institutional guidelines
and the Dutch Code of Conduct, identifiable clinical and
personal data from the patients were not available for
this study. The cell lines were cultured in 10% Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum, 25 mM HEPES buffer, 100 U/ml
penicillin, 100 μg/ml streptomycin and amphotericin
250 μg/ml. All cultures were maintained at 37°C in a
humidified atmospheric environment with 5% CO2 in
T162, T75 culture flasks or in six-well plates (for im-
munofluorescence). Cells were harvested by use of tryp-
sin (0.5% trypsin-EDTA, Invitrogen), washed once with
phosphate-buffered saline (PBS) (Fresensius Kabi Nederland
B.V.) and twice with 9 g/L NaCl (Fresensius Kabi Nederland
B.V). Passage numbers of the PEX1_1, PEX1_2, PEX1_3,
ZS, PEX6, PEX12 and control cell lines were 16–19, 16–20,
13–16, 15–20, 7–8, 19–20 and 10–20, respectively.Cell incubations
Fibroblasts were incubated for different time periods as indi-
cated, with 5, 10 or 20 mM of L-arginine monohydrochlo-
ride (MERCK, Darmstadt, Germany), 20 mM L-glutamine
(MERCK, Darmstadt, Germany) or 543 mM (=50 g/L) gly-
cerol (ACROS Organics, Geel, Belgium) added to the
culture medium. Arginine, glutamine and glycerol were
dissolved directly in the culture medium and sterilized
through a 0.45 μm filter (Millipore Millex-HP). Endogen-
ous levels of L-arginine and L-glutamine in the medium
was 3 mM and 4.4 mM respectively. Every seven days, the
cells were subcultured at a 1:2 dilution and fresh medium
was added.Catalase immunofluorescence (IF) microscopy
Catalase IF was performed essentially as described pre-
viously [15]. Fibroblasts were plated in six-well plates
containing ethanol-sterilized cover slips. The next day
(when the fibroblasts were attached), the cells were in-
cubated with the different supplements as indicated and
prepared for catalase immunofluorescence (IF) micros-
copy. To determine the effectiveness of the supplemen-
tation, the percentage of peroxisome-positive cells (cells
with punctate catalase fluorescence) was determined by
analyzing at least 200 cells in duplicate. In each experi-
ment the microscope slides were coded to prevent bias.
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Fibroblast pellets used for protein analysis, were dissolved
in a volume of 200 μl of lysis buffer (PBS, 0.25% Triton
X-100, protease inhibitor cocktail tablet (Roche, Mannheim,
Germany lot# 13690100)). Protein samples were sonicated
twice (8 watt, 40 Joule) on ice water. Protein concentration
was determined by the BCA protein assay according to
the manufacturer’s (Pierce, Rockford, USA) protocol
using human serum albumin (HSA) as standard.
Immunoblot analysis of peroxisomal thiolase was done
according to a published method [16].
Immunoblot analysis was performed with homogenates
of cultured fibroblasts (50 μg protein), separated by 10%
SDS-PAGE and transferred onto nitrocellulose by semidry
blotting. Antiserum against ACAA1 (thiolase) (Sigma-
Aldrich, St Louis, Missouri, USA) and PEX1 (BD Trans-
duction laboratories, Franklin Lakes, New Jersey, USA)
were used at a 1:2000 and 1:250 dilution respectively.
As a control for equal protein loading, we simultaneously
probed the PEX1 immunoblot with a monoclonal anti-
body against α-tubulin (Sigma-Aldrich, St Louis, Missouri,
USA), using a 1:10000 dilution. Antigen-antibody com-
plexes were visualized with IRDye 800CW goat anti-rabbit
secondary antibody for ACAA1, IRDye 800CW goat
anti-mouse antibody for PEX1, and IRDye 680RD donkey
anti-mouse secondary antibody for tubulin using the
Odyssey Infrared Imaging System (LI-COR Biosciences,
Nebraska, USA). Quantification of thiolase and PEX1
immunoblots was done using AIDA Image analyzer soft-
ware (Version 4.26, Raytest, Straubenhardt, Germany),
which allows sensitive and reliable quantification of pro-
tein amounts in a non-saturated manner.
β-oxidation of D3-C22:0 and pristanic acid
Degradation (to D3-C16:0) and elongation (to D3-C26:0)
of D3-VLCFA in intact cells was measured using D3-
C22:0 as substrate [17]. D3-C22:0 (i.e deuterium-labeled
free 22,22,22-D3-docosanoic acid) was purchased from
CDN Isotopes (Pointe-Claire Canada, lot #R259AP3).
Assays were performed in duplicate in T75 culture flasks.
Medium was replaced by fresh medium supplemented
with D3-C22:0 (6 mM dissolved in DMSO) at a final
concentration of 30 μM. After 72 hours, cells were
harvested and VLCFA analysis was done as described
before [18]. For determination of protein concentra-
tions, cells were resuspended in 200 μl deionized water
and sonicated for 10 seconds (7 Watt). Pristanic acid
β-oxidation was measured radio chemically according
to a published method [19].
Results
We studied the effect of arginine on peroxisome biogen-
esis and functioning in primary fibroblasts carrying mild
mutations in PEX1, PEX6 or PEX12. As a positive controlwe used glycerol, which we and others previously found to
have a positive effect on these parameters (not shown)
[11]. In all cell lines the mutations were found to result
in peroxisomal mosaicism when the cells were cultured
at 37°C. As a negative control we used fibroblasts from
a ZS patient (homozygous PEX1-I700fsX41), which are
completely peroxisome-deficient and as positive control
we used three cell lines from unaffected individuals. Ini-
tially, we focused on cells with PEX1 mutations, because
the PEX1 gene is by far the most commonly affected
gene in ZSDs, with the homozygous p.G843D mutation
accounting for one-tenth of all PEX1 mutations [8].
Arginine restores peroxisome biogenesis in PEX1-G843D
fibroblasts
We first studied the effect of 50 g/L glycerol (positive
control [11]) and 5, 10 and 20 mM arginine on the
number of cells with catalase-containing peroxisomes
(i.e. peroxisome-positive cells) among a total of at least
200 cells (Figure 1). We observed significant increases
in the number of peroxisome-positive cells among fibro-
blasts supplemented with arginine compared to untreated
fibroblasts (Figure 1 and Additional file 1: Figure S1).
Growth of fibroblasts in the presence of different concen-
trations of arginine resulted in an increase in the number
of peroxisome-positive cells in a concentration-dependent
manner.
To exclude a positive effect as consequence of osmotic
stress, we also incubated the cells with glutamine, which
did not have any effect on the number of peroxisome-
positive cells. Supplementation of arginine to the PEX1-
I700fsX41 cells did not result in peroxisome-positive cells
either, whereas in control fibroblasts we observed 100%
peroxisome-positive cells. Because the increase in the
number of peroxisome-positive cells when supplemented
with 5 mM arginine, was not significant, we omitted this
concentration in our further experiments.
In addition to the number of peroxisome-positive cells
accessed by catalase fluorescence, we also determined the
extent of intraperoxisomal processing of the peroxisomal
protein thiolase by immunoblots analysis (Figure 2). The
precursor of thiolase, 44 kDa, is proteolytically processed
in the peroxisome to a mature peptide of 41 kDa, as
mediated by TYNSD1 [20]. After 7 days of incubation
with arginine no increase in the amount of processed
41 kDa thiolase was observed when compared to un-
treated cells (Figure 2). However, after 14 and 21 days
of incubation with arginine or glycerol, an increasing
amount of thiolase was found to be processed in the
PEX1-G843D cell lines, indicating improved peroxisomal
import and protein processing. The addition of arginine
resulted in increased levels of processed thiolase (41 kDa)
in a concentration and time-dependent manner, while
glutamine supplementation showed no effect (Figure 2).
Figure 1 Catalase immunofluorescence of fibroblasts incubated with arginine. PEX1-G843D patient fibroblasts were incubated for 7, 14 or
21 days with different concentrations of arginine, glycerol or glutamine. Glycerol was used as a positive control. In four independent experiments,
two cover slips per condition were examined for the number of cells with catalase-containing peroxisomes among at least 200 cells. Data are
presented as means±SD, statistical analysis was performed with a two-tailed Student’s t-test, *, P < 0.05; **, P < 0.005; ***, P < 0.0005; ****, P < 0.0001
versus untreated PEX1-G843D fibroblasts. Two additional PEX1-G843D cell lines showed similar results (Additional file 1: Figure S1 and Figure 4).
Control (C) showed 100% peroxisome-positive cells. PEX1-I700fsX41 (negative control = ZS) displayed no peroxisome-positive cells.
Figure 2 Thiolase and PEX1 immunoblots. The effect of 7, 14 and 21 days incubation of PEX1-G843D cells with arginine, glycerol and
glutamine, on the amount of processed (41 kDa) peroxisomal thiolase and PEX1 protein (143 kDa) was studied by immunoblotting using cell
homogenates. The precursor of thiolase, 44 kDa, is processed in peroxisomes to a mature peptide of 41 kDa. Control showed 98% processed
thiolase, the severe cell line showed 1% processed thiolase. The faint upper band, seen in the ZS cell line with PEX1 antibody, is aspecific. Tubulin
was used to confirm equal protein loading. Data shown are representative of two independent experiments and two additional PEX1-G843D cell
lines (data not shown). ZS = severe PEX1-I700fsX41, C = Control.
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Figure 3 Effect of arginine supplementation on peroxisomal D3-C22:0, pristanic acid β-oxidation and D3-C22:0 elongation. (A) The D3-C16:0/
D3-C22:0 ratio (degradation) and (B) total amount of D3-C26:0 (elongation) was determined in three independent PEX1-G843D cell lines,
incubated for 21 days with arginine. The D3-C16:0/D3-C22:0 ratio and total amount D3-C26:0 in control cells was 2.5 (±0.5) and 0.2 (±0.1) nmol/μg
protein, respectively. In fibroblasts from the severe PEX1-I700fsX41 (ZS), the ratio and total amount was 0.002 (±0.001) and 4.2 (±0.1) nmol/μg protein,
respectively. (C) The effect of 14 days arginine incubation on the pristanic acid β-oxidation in three PEX1-G843D cell lines (PEX1_1, PEX1_2 and
PEX1_3). The pristanic acid β-oxidation in control cells was 544 (±182) pmol/hr.mg. Statistical analysis was performed with a two-tailed Student’s t-test,
p-values, when grouped, <0.0001 (figure A), 0.007 (figure B) and 0.006 (figure C). Trend in improvement of D3-C22:0 degradation and pristanic
acid β-oxidation is representative for a second independent experiment.
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cessed precursor thiolase of 44 kDa under all conditions
(data not shown).
Subsequent to thiolase immunoblot analysis we exam-
ined the total levels of PEX1 protein by immunoblot
analysis, to evaluate if arginine and glycerol supplemen-
tation had an effect on the amount of PEX1 (Figure 2).
Compared to untreated cells, we observed a minor in-
crease in PEX1 levels in mild PEX1 fibroblasts incubated
with 20 mM arginine for 21 days. In cells supplemented
with glycerol we already noted an effect after 14 days of
incubation. Because the increase in the amount of
processed thiolase in cells incubated for 7 days was not
significant, we omitted this time point in our further
experiments.Figure 4 Catalase immunofluorescence in PEX1, PEX6 and PEX12
deficient fibroblasts incubated with arginine. Shown is the effect
of 21 days incubation with 20 mM arginine on the three different
PEX1-G843D cell lines and a PEX6 and a PEX12 patient cell line. Two
independent cover slips per condition were examined by counting
the number of cells with catalase-containing peroxisomes among
at least 200 cells. Control (C) showed 100% peroxisome-positive
cells. PEX1-I700fsX41 (negative control = ZS) displayed no
peroxisome-positive cells. The data are presented as mean±SD.Arginine ameliorates the metabolic functions of
peroxisomes in PEX1-G843D fibroblasts
Patients with a mild ZSD have a (partial) deficiency in
the degradation of VLCFA (≥C22:0) due to a defect in
the peroxisomal β-oxidation, in contrast to ZS patients
in which functional capacity is fully abolished [21]. There-
fore, we investigated whether the peroxisomal VLCFA
β-oxidation, i.e. β-oxidation of D3-C22:0 to D3-C16:0
[17], in the PEX1-G843D cell lines can be restored by
addition of arginine and glycerol. It is also known that,
due to the defective peroxisomal β-oxidation, patients
with a PBD elongate the accumulating VLCFA (to C26:0)
[22]. Hence, we also studied the elongation of D3-C22:0
to D3-C26:0.
Figure 3A shows the ratio of D3-C16:0/D3-C22:0 (used
as an indication for peroxisomal β-oxidation capacity) in
three independent PEX1-G843D cell lines. Incubation
with 20 mM arginine resulted in a 4.5 to 10 fold increase
in the β-oxidation of D3-C22:0 in the three PEX1 cell
lines, indicating improved peroxisomal functioning. No
effect of arginine supplementation on peroxisomal β-
oxidation in control and ZS fibroblasts was observed.
Furthermore, incubation with glutamine did not show
an effect on the β-oxidation of D3-C22:0 to D3-C16:0. In
addition to an increased peroxisomal β-oxidation, the
arginine supplementation also leads to decreased elong-
ation rates of D3-C22:0 to D3-C26:0 (Figure 3B).Because ZSD patients also have a (partial) defect in
the β-oxidation of pristanic acid [23,24], we also studied
the effect of arginine and glycerol on peroxisomal
pristanic acid oxidation. PEX1-G843D cell lines showed a
residual pristanic acid β-oxidation capacity of approxi-
mately 10 to 50 pmol/hr.mg. However, upon arginine
incubation, the fibroblasts showed a 3 to 15 fold in-
crease in pristanic acid β-oxidation capacity (Figure 3C).
Glycerol caused an even larger increase to approximately
50 to 220 pmol/hr.mg. Fibroblasts from the ZS cell line
showed no increase in pristanic acid β-oxidation when
incubated with arginine or glycerol.
Improvement of peroxisomal biogenesis in PEX6 and
PEX12 mutant fibroblasts
Following the positive effects in the PEX1 cell lines, we
also investigated the effect of arginine in specific PEX6
and PEX12 cell lines. Both cell lines display peroxisomal
mosaicism, with PEX12-p.S320F being the most common
PEX12 mutation. This mutation is common in patients
from Turkish descent [8]. As observed in the PEX1 cell
lines, the addition of 20 mM arginine for 21 days resulted
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(Figure 4) indicating that the effect of arginine is not
mutation specific.
Discussion
Currently, there is no cure for ZSDs and possibilities for
supportive and symptomatic treatment are limited. Some
patients received docosahexaenoic acid without any proven
positive effect [25]. In addition, some patients follow a
phytanic acid reduced diet and are supplemented with
fat-soluble vitamins [26]. Previous studies revealed a
close correlation between the clinical/biochemical severity
and the functional consequences of the PEX mutations on
the encoded protein in cells from patients with a PBD
[27]. Among the reported mutations in the PEX1 gene,
which is most commonly defective, the PEX1-G834D
mutation is associated with a mild clinical phenotype
and relatively mild biochemical and cellular abnormal-
ities [27-30].
In the present study, we investigated the effect of
arginine and glycerol on peroxisome biogenesis and
functioning in a subset of specific PEX1, PEX6 or
PEX12-defective fibroblasts, that all display peroxisomal
mosaicism. Previous studies have shown that these cell
lines showed improved peroxisomal function, when cul-
tured at 30°C, suggesting a problem in protein folding.
Furthermore Zhang et al., 2010 [11] observed a positive
effect of several compounds on peroxisomal function in
cell lines with the PEX1-G834D mutation. To study
whether the presumed protein folding problem can be
improved, we incubated these cell lines with arginine or
glycerol, two known chemical chaperones in vitro [12].
Our results show a significant increase in the amount of
peroxisome-positive cells, the intraperoxisomal processing
of thiolase, the β-oxidation of D3-C22:0 (to D3-C16:0)
and pristanic acid and a decrease in the elongation of
D3-C22:0 (to D3-C26:0) in homozygous PEX1-G843D
fibroblasts incubated with arginine. The mild untreated
PEX1 cell lines showed similar values of D3-C26:0 com-
pared to the ZS cell line. This implies that untreated mild
PEX1 cell lines are not sufficiently metabolic active to res-
cue the elongation of D3-C22:0 to D3-C26:0. However,
upon arginine supplementation, we observed decreased
levels of D3-C26:0 levels. Furthermore, we found a positive
effect of arginine on the amount of peroxisome-positive
cells in specific PEX6 and PEX12 cell lines.
Despite the apparent improvement in peroxisome bio-
genesis and functioning, we only found a small increase
in the amount of PEX1 protein upon immunoblot analysis
of cell homogenates incubated for 21 days with 20 mM
arginine. Apparently, the improvement in peroxisomal
function is not accompanied by an obvious increase in
total amount of PEX1 protein. Unfortunately, with immu-
noblot analysis, we cannot discriminate between incorrectlyand correctly folded PEX1 protein, but we assume that
arginine results in higher levels of correctly folded PEX1-
G843D protein.
Osmotic stress can induce heat shock proteins, which
enhance improved protein folding [31]. To exclude that
the improvement of arginine was due to such an osmotic
stress effect, we incubated the cells with comparable
concentrations of glutamine. Glutamine is also an amino
acid, but has no known chaperone properties. Overall,
we did not observe any effect on peroxisome biogenesis
and functioning upon glutamine supplementation.Conclusion
Although incubation with glycerol showed a more potent
effect than arginine, the concentration used to reach this
effect is too high (i.e. 543 mM) for potential clinical ap-
plication. However, because plasma arginine concentra-
tions can reach levels from up to 6 mM in humans and
arginine supplementation is given to other diseases, in-
cluding MELAS-syndrome [32], for which few side-effect
are reported, we believe that arginine supplementation
may provide a potential therapy for mild ZSD patients. In
MELAS syndrome, arginine is thought to function as a
nitric oxide stimulator rather than a chemical chaperone.
It has been suggested that arginine activates the produc-
tion of nitric oxide and thereby the induction of stress
and upregulation of heat shock proteins [33]. It is pos-
sible that also in our study arginine activates this nitric
oxide-mediated pathway and induces the expression of heat
shock proteins to improve folding. This will be addressed
in future studies.
Finally, given the fact that peroxisomal disorders are
neurological diseases it is interesting to note that arginine
can cross the blood–brain-barrier [34].Additional file
Additional file 1: Figure S1. Catalase immunofluorescence of
fibroblasts incubated with arginine. Two additional PEX1-G843D patient
fibroblasts were incubated for 7, 14 and 21 days with arginine, glycerol
and glutamine. Glycerol was used as a positive control. In four independent
experiments, two cover slips per condition were examined for the number
of cells with catalase-containing peroxisomes among at least 200 cells.
Data are presented as means ± SD, statistical analysis was performed
with a two-tailed Student’s t-test, *, P < 0.05; **, P < 0.005; ***, P < 0.0005;
****, P < 0.0001 versus untreated PEX1-G843D fibroblasts. Control showed
100% peroxisome positive cells. PEX1-I700fsX41 (negative control) showed
no peroxisome positive cells.Abbreviations
D3: Deuterium-labeled; D3-C22:0: Deuterium-labeled free 22,22,22-D3-
docosanoic acid; DMEM: Dulbecco’s Modified Eagle’s Medium; IRD: Infantile
refsum disease; MELAS: Mitochondrial encephalomyopathy lactic acidosis
and stroke-like episodes; NALD: Neonatal adrenoleukodystrophy;
PBD: Peroxisome biogenesis disorder; VLCFA: Very long chain fatty acids;
ZSD: Zellweger spectrum disorder; ZS: Zellweger syndrome.
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